CAS 1613695-14-9

SGC-CBP30

Description:

SGC-CBP30, with the CAS number 1613695-14-9, is a small molecule inhibitor that specifically targets the bromodomain and extraterminal (BET) family of proteins, particularly BRD4. This compound is known for its role in modulating gene expression by disrupting the interaction between BET proteins and acetylated lysines on histones, which is crucial for the transcriptional regulation of various genes involved in cancer and inflammation. SGC-CBP30 has been studied for its potential therapeutic applications in various cancers, as it may help in reducing the proliferation of cancer cells by altering the expression of oncogenes. Additionally, it has shown promise in preclinical studies for its ability to penetrate cells effectively and exhibit selective inhibition. The compound is typically characterized by its molecular structure, which includes specific functional groups that contribute to its biological activity. As research continues, SGC-CBP30 may provide insights into the development of novel treatments targeting BET proteins in various diseases.

2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-4-isoxazolyl)-1-[(2S)-2-(4-morpholinyl)propyl]-1H-benzimidazole

CAS: 1613695-14-9

Formula: C₂₈H₃₃ClN₄O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 509.0396

Ref: IN-DA00ABLP

SGC-CBP30

CAS: 1613695-14-9

SGC-CBP30

Purity: ≥98%

Molecular weight: 509.04g/mol

Ref: 54-BUP03006

SGC-CBP30

CAS: 1613695-14-9

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).

Formula: C₂₈H₃₃ClN₄O₃

Purity: 99.05% - >99.99%

Color and Shape: Solid

Molecular weight: 509.04

Ref: TM-T6668

SGC-CBP30

CAS: 1613695-14-9

Purity: 98%

Molecular weight: 509.049987792969

Ref: 10-F800085

SGC-CBP30

Controlled Product

CAS: 1613695-14-9

Formula: C₂₈H₃₃ClN₄O₃

Color and Shape: Neat

Molecular weight: 509.04

Ref: TR-S282310

2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole

CAS: 1613695-14-9

2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole (DCPI) is a cancer drug that inhibits the activity of DNA topoisomerase II. It is used to treat cancers that are resistant to other cancer drugs. DCPI is a potent inhibitor of DNA topoisomerase II and has been shown to be effective in treating multiple myeloma and acute lymphoblastic leukemia. DCPI binds to the active site of DNA topoisomerase II and prevents its cleavage of dsDNA, which leads to cell death by preventing the synthesis of proteins essential for cell division.

Formula: C₂₈H₃₃ClN₄O₃

Purity: Min. 95%

Molecular weight: 509.05 g/mol

Ref: 3D-NPC69514